- PR Newswire•7 days agoaTyr Pharma Appoints Industry Veteran in Novel Biology Biologics, David J. King, PhD, as Senior Vice President, Research
SAN DIEGO, Sept. 21, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (LIFE), today announced that David J. King, PhD, has joined the company as Senior Vice President, Research. Dr. King will lead aTyr's research and preclinical efforts to advance its Physiocrine biology and support the clinical development of meaningful medicines that target immune and tissue homeostatic pathways for patients with various severe and rare diseases. "Dr. King is uniquely qualified to help us execute on our mission to bring Physiocrine-based therapeutic candidates to patients with severe and rare diseases," said John Mendlein, PhD, Chief Executive Officer of aTyr Pharma.
- TheStreet.com•13 days ago
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
- Associated Press•2 months ago
The San Diego-based company said it had a loss of 65 cents per share. In the final minutes of trading on Wednesday, the company's shares hit $2.98. A year ago, they were trading at $18.13. _____ This story ...
aTyr Pharma Inc. (LIFE)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||3.30 x 200|
|Ask||3.33 x 100|
|Day's Range||3.28 - 3.34|
|52wk Range||2.48 - 13.26|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-1.33|
|Avg Vol (3m)||223,240|
|Dividend & Yield||N/A (N/A)|